Rosacea Treatment Options
Rosacea affects an estimated 5–10% of the global population, yet fewer than half receive a formal diagnosis. Modern rosacea management uses a combination of topical therapies, oral medications, and procedural interventions tailored to your specific subtype and symptom severity. Most patients see meaningful improvement within 4–12 weeks of consistent treatment. This guide summarises the clinical evidence behind each major option so you can have an informed conversation with your dermatologist.
How Rosacea Treatment Works
Rosacea treatment follows a stepwise approach. The 2019 ROSCO expert consensus panel recommends beginning with gentle skincare and sun protection as the baseline, then layering targeted therapies based on the dominant phenotype - whether that is persistent erythema (redness), papules and pustules, phymatous changes, or ocular involvement. Studies show that up to 78% of patients achieve significant improvement when following a structured, phenotype-based treatment protocol [1].
Most treatment plans combine two or more modalities. For example, a patient with papulopustular rosacea may use topical ivermectin alongside low-dose doxycycline during an active flare, then taper to topical maintenance only. Consistency is more important than intensity - clinical trials consistently show that 12-16 weeks of steady use outperforms intermittent treatment, with relapse rates 40–60% lower in patients who maintain a consistent routine [2].
The goal is not "perfect skin" overnight. It is gradual, measurable improvement: fewer papules per week, shorter flare duration, and reduced background redness over months. On average, patients report meaningful quality-of-life improvement within 6-8 weeks of starting treatment. Tracking your symptoms - even in a simple diary - helps identify whether a treatment is working and when adjustments are needed.
Topical Treatments
First-line options applied directly to the skin to reduce redness, bumps, and inflammation.
Ivermectin 1% cream (Soolantra)
Ivermectin 1% cream (brand name Soolantra) is a once-daily topical treatment for papulopustular rosacea that works by killing Demodex folliculorum mites and reducing skin inflammation simultaneously. In clinical trials it achieved 83% inflammatory lesion reduction at 16 weeks, making it one of the most effective first-line topical options available.
Ivermectin has a dual mechanism: it is both anti-inflammatory and anti-parasitic, reducing Demodex folliculorum mite density in the skin. Elevated Demodex populations are found in up to 60–80% of papulopustular rosacea patients, and their die-off can trigger inflammation [3].
Clinical evidence: Two pivotal Phase III trials (ATTRACT I & II) compared ivermectin 1% once daily to metronidazole 0.75% twice daily over 16 weeks. Ivermectin achieved significantly greater reduction in inflammatory lesion count (83% vs 73.7% improvement) and a higher proportion of "clear" or "almost clear" ratings on the Investigator Global Assessment (IGA) scale [4].
How to use: Apply a pea-sized amount once daily (evening) to affected areas after cleansing. Initial worsening (die-off reaction) is common in weeks 2-4 and typically resolves by week 6–8.
Side effects: Mild burning or stinging in the first few days. The die-off flare is temporary and is a sign the treatment is working.
Azelaic acid 15% gel
Azelaic acid 15% gel is a multi-pathway topical treatment for rosacea that reduces inflammation, neutralises reactive oxygen species, and suppresses the cathelicidin cascade responsible for redness. Applied twice daily, it achieves "clear" or "minimal" disease in 56–58% of patients by week 12 and is available without prescription at lower strengths in some countries.
Azelaic acid works through multiple pathways: it inhibits reactive oxygen species (ROS), suppresses kallikrein-5 (KLK5) activity (reducing cathelicidin production), and has mild antibacterial properties. This makes it effective for both inflammatory lesions and post-inflammatory erythema [5].
Clinical evidence: A randomised controlled trial by Thiboutot et al. (2003) demonstrated that 15% azelaic acid gel applied twice daily achieved "clear" or "minimal" disease in 56–58% of patients at 12 weeks, significantly better than vehicle (40%) [6].
How to use: Apply a thin layer twice daily (morning and evening) to clean skin. Can be used under sunscreen and moisturiser. In some countries, 10% formulations are available over the counter.
Side effects: Mild tingling or stinging on application (usually resolves within minutes). Rarely causes dryness if skin barrier is compromised.
Metronidazole 0.75%–1% (gel or cream)
Metronidazole 0.75%–1% is one of the longest-established topical treatments for papulopustular rosacea, in clinical use since the 1980s. It reduces oxidative stress and neutrophil-driven inflammation applied once or twice daily. Clinical trials show 55–65% lesion count reduction at 12 weeks with a well-established safety profile spanning over 35 years of dermatological prescribing.
Metronidazole has been a rosacea treatment standard since the 1980s. Its exact mechanism in rosacea is not fully understood, but it appears to reduce oxidative stress and neutrophil-generated inflammation rather than acting through its antibiotic activity [7].
Clinical evidence: Multiple RCTs confirm efficacy for papulopustular rosacea, with typical lesion count reductions of 55–65% at 12 weeks. It remains a valid first-line option, particularly for patients with mild-to-moderate disease or those who prefer a well-established treatment with decades of safety data [8].
How to use: Apply once or twice daily depending on formulation strength. Available as 0.75% gel/lotion (twice daily) or 1% cream (once daily).
Side effects: Generally well-tolerated. Occasional dryness or mild stinging. No systemic absorption concerns at topical doses.
Brimonidine 0.33% gel & Oxymetazoline 1% cream
Brimonidine (Mirvaso) and oxymetazoline (Rhofade) are alpha-adrenergic agonist topicals that temporarily constrict dilated facial blood vessels, reducing visible redness within 30 minutes of application. Effects last 8–12 hours. Unlike anti-inflammatory treatments that target bumps and pustules, these address persistent background erythema — the diffuse facial flush that up to 90% of rosacea patients report as their most distressing symptom.
These are alpha-adrenergic agonists that work differently from anti-inflammatory topicals — they temporarily constrict dilated facial blood vessels, reducing visible redness (erythema) rather than targeting papules or pustules. They address the "background flush" that many patients find most distressing [9].
Clinical evidence: Brimonidine (Mirvaso) showed peak erythema reduction at 3–6 hours post-application in Phase III trials, with effects lasting up to 12 hours. Oxymetazoline (Rhofade) demonstrated more gradual onset with fewer reported rebound flares [10].
Important note: Some patients experience rebound redness (worsening after the effect wears off), particularly with brimonidine. Starting with a small test area and gradual frequency increase can reduce this risk. These are best used as "event-day" treatments rather than daily staples for some patients.
Learn more about ingredient tolerance in the ingredient guide.
Oral Treatments
Systemic medications used for moderate-to-severe inflammation, frequent flares, or when topicals alone are insufficient.
Low-dose doxycycline (40mg modified-release)
Low-dose doxycycline (40mg modified-release) is an oral anti-inflammatory medication for moderate-to-severe papulopustular rosacea. At this sub-antimicrobial dose it inhibits matrix metalloproteinases without contributing to antibiotic resistance. Clinical trials show significant inflammatory lesion reduction within 3–4 weeks, with 8–16 week treatment courses being standard. It is the only FDA-approved oral therapy specifically indicated for rosacea.
At 40mg, doxycycline operates below its antimicrobial threshold and functions purely as an anti-inflammatory. It inhibits matrix metalloproteinases (MMPs) and reduces pro-inflammatory cytokines, which drive rosacea's vascular and inflammatory pathology [11].
Clinical evidence: The landmark study by Del Rosso et al. confirmed that 40mg modified-release doxycycline significantly reduced inflammatory lesion counts versus placebo at 16 weeks, without promoting antibiotic resistance — a critical advantage over traditional 100mg dosing [12].
How to use: One capsule daily, usually taken in the morning with food. Treatment courses typically run 8–16 weeks, though some patients remain on long-term low-dose maintenance under medical supervision.
Side effects: Mild nausea (reduced by taking with food), photosensitivity (use daily sunscreen), and rare oesophageal irritation (do not lie down within 30 minutes of taking).
Low-dose isotretinoin
Low-dose isotretinoin (0.1–0.3 mg/kg/day) is a systemic retinoid reserved for treatment-resistant papulopustular or phymatous rosacea that has failed topical and standard oral therapies. It reduces sebaceous gland activity and deep inflammation over 4–6 month courses. Systematic reviews report complete or marked improvement in 60–80% of refractory cases, though it requires strict medical monitoring.
For treatment-resistant papulopustular or phymatous rosacea, low-dose isotretinoin (0.1–0.3 mg/kg/day) can be effective. Unlike acne dosing, rosacea isotretinoin uses lower doses for longer periods, reducing sebaceous gland activity and inflammation while minimising side effects [13].
Clinical evidence: A systematic review by van Zuuren et al. found low-dose isotretinoin achieved complete or marked improvement in 60–80% of patients with refractory papulopustular rosacea, though relapse rates after discontinuation ranged from 20–50% [14].
Important note: Isotretinoin is teratogenic (causes birth defects) and requires strict pregnancy prevention programmes. Regular blood monitoring for liver function and lipids is required. It is typically reserved for cases that have failed other options.
Beta-blockers (off-label for flushing)
Beta-blockers (carvedilol, propranolol) are used off-label for rosacea patients whose dominant symptom is severe, recurrent flushing rather than bumps or pustules. They block sympathetic nervous system–driven vasodilation, reducing flush intensity and frequency. This is a specialist-level prescription typically reserved for neurogenic rosacea when other options have not controlled flushing episodes.
For patients whose dominant symptom is severe, frequent flushing rather than papules, non-selective beta-blockers like carvedilol or propranolol can reduce the intensity and frequency of flush episodes by blocking sympathetic nervous system–driven vasodilation.
Clinical evidence: This is an off-label use with limited but promising evidence. Small studies and case series report meaningful reduction in flushing episodes, particularly in patients with neurogenic rosacea driven by emotional or thermal triggers [15].
Important note: These require careful medical supervision due to effects on blood pressure and heart rate. They are not appropriate for everyone and are typically a specialist-level prescription.
Laser & Light-Based Treatments
Procedural options for persistent redness, visible blood vessels (telangiectasia), and flushing that do not respond adequately to topicals.
Pulsed Dye Laser (PDL) - 585/595nm
Pulsed dye laser (PDL) at 585/595nm is the gold-standard procedural treatment for visible telangiectasia and localised redness in rosacea. It selectively destroys dilated blood vessels through photothermolysis without damaging surrounding tissue. A typical course of 3–5 sessions spaced 4–6 weeks apart achieves 50–75% improvement in visible vessels, with annual maintenance sessions to address new vessel formation.
The pulsed dye laser targets oxyhaemoglobin in dilated blood vessels, causing selective photothermolysis - the vessel is heated and destroyed without damaging surrounding tissue. It is considered the gold standard for treating visible telangiectasia and localised redness [16].
Typical protocol: 3–5 sessions spaced 4–6 weeks apart. Most patients see 50–75% improvement in visible vessels after a full course. Maintenance sessions (1–2 per year) may be needed as new vessels can form over time.
Side effects: Temporary purpura (bruising) lasting 7–10 days at higher settings, mild swelling, and transient redness. Non-purpuric settings reduce downtime but may require more sessions.
Intense Pulsed Light (IPL) - 500–1200nm
Intense pulsed light (IPL) is a broad-spectrum light therapy (500–1200nm) used for diffuse facial redness and widespread flushing in rosacea. It covers larger areas per pulse than laser, making it ideal for general background erythema. Studies show patient satisfaction rates above 80% after 3–5 sessions. IPL is most effective for Fitzpatrick skin types I–III and requires periodic maintenance treatments.
IPL uses broad-spectrum light filtered to target blood vessels and melanin. It covers larger treatment areas per pulse than PDL, making it well-suited for diffuse background erythema and widespread flushing patterns rather than individual vessels [17].
Clinical evidence: A study by Neuhaus et al. demonstrated significant reduction in erythema scores after 3–5 IPL sessions, with patient satisfaction rates above 80%. IPL may also improve skin texture and reduce Demodex density through thermal effects.
Limitations: Less precise than PDL for isolated telangiectasia. Not suitable for darker skin tones (Fitzpatrick V–VI) due to melanin absorption risk. Results require maintenance treatments.
Nd:YAG laser - 1064nm
Nd:YAG laser (1064nm) is a deep-penetrating vascular laser used for larger or deeper blood vessels that shorter-wavelength lasers cannot reach. Its longer wavelength has lower melanin absorption, making it safer for darker skin tones (Fitzpatrick III–V). It is particularly effective for nasal telangiectasia and deeper vascular lesions, often used in combination with PDL for comprehensive redness treatment.
The longer wavelength of Nd:YAG penetrates deeper into the skin, making it effective for larger, deeper vessels that PDL cannot reach. It is also safer for darker skin tones because the 1064nm wavelength has lower melanin absorption [16].
Best for: Larger telangiectasia (especially on the nose), deeper vascular lesions, and patients with Fitzpatrick skin types III–V who are not ideal IPL candidates.
Side effects: Higher risk of pain during treatment (cooling devices are used). Temporary swelling and redness. Small risk of scarring if settings are too aggressive.
Supportive Skincare
The foundation that makes prescription treatments work better.
Barrier-first routine
A compromised skin barrier amplifies every rosacea trigger. Clinical guidelines recommend a minimal routine: a fragrance-free, non-foaming cleanser (pH 5.5); a ceramide or niacinamide-based moisturiser to restore barrier lipids; and a broad-spectrum mineral sunscreen (SPF 30+) applied daily regardless of weather [1].
Niacinamide (vitamin B3) at 4-5% concentration has additional anti-inflammatory benefits in rosacea and can be found in many over-the-counter moisturisers. It strengthens the barrier, reduces transepidermal water loss (TEWL), and has been shown to reduce redness in mild rosacea even as a standalone ingredient.
Key principle: Prescription topicals work best on calm, hydrated skin. If the barrier is inflamed and irritated, even gentle treatments can sting and cause poor adherence. Fix the barrier first, then introduce active treatments gradually.
When to See a Dermatologist
Seek professional evaluation if your symptoms are worsening despite consistent treatment, if you notice eye involvement (grittiness, burning, lid margin redness - signs of ocular rosacea), or if you develop thickening of skin tissue on the nose or other areas (possible phymatous changes) [1].
A dermatologist can perform dermoscopy to confirm your diagnosis, differentiate rosacea from lupus or seborrhoeic dermatitis, and prescribe combination therapies not available over the counter. Early intervention in progressive subtypes prevents irreversible tissue changes.
This page is informational and does not replace personalised medical advice.
References
- Schaller M, et al. "Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel." Br J Dermatol. 2017;176(2):465-471.
- van Zuuren EJ, et al. "Interventions for rosacea." Cochrane Database Syst Rev. 2015;(4):CD003262.
- Forton FMN, De Maertelaer V. "Two consecutive standardized skin surface biopsies: an improved sampling method to evaluate Demodex density." Acta Derm Venereol. 2017;97(2):242–248.
- Taieb A, et al. "Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea (ATTRACT)." Br J Dermatol. 2015;172(4):1103–1110.
- Mastrofrancesco A, et al. "Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARγ activation." Exp Dermatol. 2010;19(9):813–820.
- Thiboutot D, et al. "Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea." J Am Acad Dermatol. 2003;48(6):836–845.
- Nielsen PG. "Metronidazole treatment in rosacea." Int J Dermatol. 1988;27(1):1–5.
- Dahl MV, et al. "Topical metronidazole maintains remissions of rosacea." Arch Dermatol. 1998;134(6):679–683.
- Fowler J, et al. "Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea." J Drugs Dermatol. 2012;11(10):1158–1164.
- Draelos ZD, et al. "Pharmacokinetics of topical oxymetazoline in adults with persistent facial erythema of rosacea." J Clin Aesthet Dermatol. 2018;11(6):28–32.
- Del Rosso JQ. "Anti-inflammatory dose doxycycline in the treatment of rosacea." J Clin Aesthet Dermatol. 2009;2(3):40–43.
- Del Rosso JQ, et al. "Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline administered once daily for treatment of rosacea." J Am Acad Dermatol. 2007;56(5):791–802.
- Park YJ, et al. "Low-dose isotretinoin therapy for refractory rosacea." Ann Dermatol. 2014;26(6):718–722.
- van Zuuren EJ, et al. "Interventions for rosacea: abridged updated Cochrane systematic review." J Am Acad Dermatol. 2015;73(1):171–175.
- Hsu CC, Lee JY. "Carvedilol for the treatment of refractory facial flushing and persistent erythema of rosacea." Arch Dermatol. 2011;147(11):1258–1260.
- Alam M, et al. "Comparative effectiveness of nonpurpuragenic 595-nm pulsed dye laser and microsecond 1064-nm neodymium:yttrium-aluminum-garnet laser for treatment of diffuse facial erythema." J Am Acad Dermatol. 2013;69(3):438–443.
- Neuhaus IM, et al. "Light-based treatments for rosacea." Dermatol Ther. 2009;22(3):211–217.
Frequently Asked Questions
Common questions about rosacea treatments, answered clearly.
1What are the most effective treatments for rosacea?
Effective treatments depend on subtype and severity. Common options include topical azelaic acid, metronidazole, or ivermectin; oral medications like doxycycline; and laser or IPL for redness and visible vessels. A dermatologist can help tailor the plan.
2Can over-the-counter products treat rosacea?
Some OTC ingredients like azelaic acid (available at 10% without prescription in some countries) or low-strength niacinamide can support rosacea-prone skin, but prescription treatments are usually required for persistent papules, pustules, or progressive redness. Always patch test new products on a small area first.
3Does laser treatment help rosacea redness?
Yes. Vascular lasers (pulsed dye laser, Nd:YAG) and IPL can reduce visible blood vessels and background redness, especially for erythematotelangiectatic rosacea. Most people need 3–5 sessions spaced 4–6 weeks apart, with maintenance treatments once or twice a year.
4How long does it take for rosacea treatment to work?
Most topical treatments take 4–12 weeks to show meaningful improvement. Ivermectin may initially cause a temporary worsening (die-off reaction) before things improve around week 4–6. Oral doxycycline typically shows results within 3–4 weeks. Laser results are visible after each session but full improvement builds over the treatment course.
5Can you cure rosacea permanently?
There is currently no permanent cure for rosacea. However, many people achieve long-term remission with consistent treatment, trigger avoidance, and a protective skincare routine. Laser therapy can permanently reduce visible vessels, and ongoing low-maintenance treatment can keep flares at bay.
6Is doxycycline safe for long-term use in rosacea?
Low-dose doxycycline (40mg modified-release) is approved for long-term use because it works as an anti-inflammatory at this dose rather than an antibiotic. It does not contribute to antibiotic resistance at sub-antimicrobial doses. Common side effects include mild nausea and sun sensitivity. Your doctor will monitor as needed.
7What is the difference between ivermectin and metronidazole for rosacea?
Both are prescription topicals for papulopustular rosacea. Ivermectin (Soolantra) targets Demodex mites and inflammation, applied once daily. Metronidazole is purely anti-inflammatory, applied once or twice daily. Head-to-head trials (ATTRACT study) showed ivermectin was more effective at 16 weeks, but both are valid first-line options depending on your presentation.
Related Resources
How to Get the Best from Soolantra
The 8-dot technique, die-off, and consistency tips
Treatment by Subtype
ETR vs papulopustular vs ocular
Rosacea Types
Match treatments to your subtype
How Rosacea Is Diagnosed
Understand diagnostic criteria
Calm a Flare Fast
Short, actionable relief steps
Ingredient Guide
See what helps or irritates
Triggers & Tracking
Reduce flare frequency